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temporal persistence.Background Clinical classiﬁcation of AF is employed to communicate its persistence, to select appropriate therapies, and as
inclusion criterion for clinical trials.Methods Cardiac rhythm histories of 1,195 patients (age 73.0  10.1 years, follow-up: 349  40 days) with implantable
devices were reconstructed and analyzed. Patients were classiﬁed as having paroxysmal or persistent AF by
physicians at baseline in accordance with current guidelines. AF burden, measured as the proportion of time spent in
AF, was obtained from the device. Additionally we evaluated the agreement between clinical and device-derived AF
classiﬁcations.Results Patients within the same clinical class were highly heterogeneous with regards to AF temporal persistence.
Agreement between the clinical AF classiﬁcation and the objective device-derived assessments of AF temporal
persistence was poor (Cohen’s kappa: 0.12 [95% CI: 0.05 to 0.18]). Patient characteristics inﬂuenced the clinical
decision to classify AF as paroxysmal or persistent. Higher ejection fraction (odds ratio: 0.97/per unit [95% CI: 0.95
to 0.98/per unit]; p < 0.0001) and presence of coronary artery disease (odds ratio: 0.53 [95% CI: 0.32 to 0.88];
p ¼ 0.01) were independently associated with a lower probability of being classiﬁed as persistent AF for the same
AF burden level.Conclusions The currently used clinical AF classiﬁcations poorly reﬂect AF temporal persistence. Patient characteristics
signiﬁcantly inﬂuence the physician’s classiﬁcation of AF. Patients classiﬁed in identical clinical categories may
be inherently heterogeneous with regard to AF temporal persistence. Further study is required to determine if
patient selection on the basis of objective criteria derived from rigorous AF monitoring can improve reported
outcomes and better identify responders and non-responders to treatments. (OMNI Study–Assessing Therapies
in Medtronic Pacemaker, Deﬁbrillator, and Cardiac Resynchronization Therapy Devices; NCT00277524; TRENDS:
A Prospective Study of the Clinical Signiﬁcance of Atrial Arrhythmias Detected by Implanted Device Diagnostics;
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2841pharmacological or electrical cardioversion), long-standing
persistent (AF lasting1 year and a rhythm control strategy is
decided), and permanent (when the arrhythmia is accepted
and rhythm control is no longer pursued). Both statements
recognize the high uncertainty in diagnosing AF on the basis
of symptoms (1–4) or intermittent rhythm monitoring
(1,2,5,6).
These clinical classiﬁcations are used to individualize the
choice of rate or rhythm control strategies and to select
appropriate medical or interventional therapies for each AF
patient. For example, although patients classiﬁed as having
paroxysmal or persistent AF are generally indicated for
rhythm control, patients with permanent AF are usually
treated with rate control strategies. Additionally, the success
of cardioversion efforts has been shown to be related to the
duration of AF, which is partly communicated through the
AF classiﬁcation (1,7).
The clinical AF classiﬁcations are also employed to select
patients for inclusion in clinical trials (8) with the primary
intention to build groups of patients with similar arrhythmia
magnitude and persistence in order to draw valid inferences
regarding the effect of a treatment between the control and
the treatment group.
The aim of the present study was 2-fold. First, we sought
to assess how accurately the clinical AF classiﬁcations
(“paroxysmal,” “persistent”) reﬂect the temporal persistence
of AF (i.e., how much time a patient is in AF). Second, we
assessed the homogeneity of patients classiﬁed in the same
clinical AF classiﬁcation. To accurately evaluate the tem-
poral persistence of AF, we analyzed patients who were
continuously monitored via implantable devices.Methods
Population characteristics. We included patients enrolled
in the OMNI (9) and TRENDS (10–13) clinical trials. In
brief, the inclusion criteria for the OMNI trial were the
presence of a speciﬁc model of Medtronic (Minneapolis,
Minnesota) device (InSync Sentry [CRT-D], EnTrust
[ICD-VR and DR systems], Instrinsic [ICD-DR], and
EnRhythm [IPG-DR]) in patients 18 years of age or older.
Inclusion criteria for the TRENDS study were an estab-
lished Class I/II indication for an implantable cardiac
rhythm device capable of long-term trending of atrial
tachycardia or AF burden and at least 1 of the following risk
factors for stroke: congestive heart failure, hypertension,
65 years of age or older, diabetes mellitus, or prior stroke
or transient ischemic attack. In the OMNI trial, single
chamber devices and devices that did not have an atrial lead
were excluded because of their inability to detect AF.
Patients from the TRENDS trial were excluded from this
analysis if they had an attempted cardioversion or AF
ablation anytime during follow-up, underwent device re-
placements, already had permanent atrial tachycardia/AF,
had known re-entrant supraventricular tachycardia, or had a
terminal illness.From the initial population
of the OMNI (n ¼ 737) and
TRENDS (n ¼ 598) trials and
for the purposes of the present
analysis, we excluded 60 patients
with AF speciﬁc treatments
(medical/electrical cardioversion
or catheter ablation), 27 patients
with single chamber devices, and
7 patients in whom no atrial lead
was implanted. The total popu-
lation (n ¼ 1,195) included patients with at least 180 days of
documented rhythm history from the device trending data
(Cardiac Compass, Medtronic Inc., Minneapolis, Minne-
sota) and the analyzed follow up duration was limited to 365
days in order to avoid having progression of AF as a con-
founding factor.
Clinical AF classiﬁcation was performed according to
AHA guidelines just prior to device implantation (1). The
OMNI and TRENDS trials studied the magnitude of AF
on clinical outcomes and collected data on patients’ clinical
management, and careful attention was paid to the clinical
classiﬁcation of the patients’ AF according to the AHA
guidelines (1).
Additionally, we sought to compare the degree of
agreement between the clinical AF classiﬁcations with a
device-derived AF classiﬁcation on the basis of objective,
device-derived criteria. For the device-derived AF classiﬁ-
cation, we used the following deﬁnitions: no AF: no day with
>5 min of AF (11,13,14); paroxysmal AF: at least 1 day with
>5 min of AF but <7 consecutive days with >23 h of AF;
persistent AF: at least 7 consecutive days with >23 h of AF
(15,16); permanent AF: All days with >23 h of AF (or
>95% AF burden) (17). Although these device-based def-
initions may seem somewhat arbitrary, they were designed to
align with published guidelines (1) and have been used in
several AF trials (11,13–17). Device-derived deﬁnitions have
the advantage of being consistent and reproducible, and are
based on objective temporal AF indices.
AF burden was deﬁned as the proportion of the monitored
time that a patient was in AF. AF density, as described
previously (6,18), characterized the temporal aggregation of
the AF burden. In short, AF density is a quantitative measure
of the temporal aggregation of AF burden and was calculated
as an index consisting of values between 0 (AF burden evenly
spread over the observation time) and 1 (maximal possible
AF burden aggregation; i.e., “one continuous episode of
AF”). A thorough presentation of the AF density has been
reported previously (6,18). The AF detection algorithms
utilized in the study devices have been evaluated extensively
and have been shown to quantify AF burden with 99%
accuracy (19–21).
Statistical analyses. Simple statistical tests (such as the
t test, chi-square test, Mann-Whitney U test, analysis of
variance, and Kruskal-Wallis tests) were employed where
appropriate to identify differences in the demographics of
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2842the patient population subgroups. The agreement between
clinical and device AF classiﬁcations was evaluated using
Cohen’s kappa. Logistic and multinomial logistic regression
was used to investigate the inﬂuence of patient demo-
graphics on the AF classiﬁcation. The temporal persistence
of AF as measured by the AF burden was signiﬁcantly
associated with the clinical AF classiﬁcation and was
included in subsequent models investigating the additional
effect of the following variables on the clinical AF classiﬁ-
cation: age, sex, presence of coronary artery disease, presence
of cardiomyopathy, functional status (New York Heart As-
sociation functional class), history of ablation for AF, history
of heart surgery, AF density (6,18), and left ventricular
ejection fraction (LVEF). Receiver-operating characteristic
analyses were used to evaluate the performance of AF
burden as a discriminator of the clinical AF classiﬁcation.
The p values of 2-sided tests at a signiﬁcance level of 0.05
are reported.
All statistical analyses were performed with R version 3.0.1
(R Development Core Team 2013, Vienna, Austria) (22).Results
General demographics. General demographics and char-
acteristics for the 1,195 patients included in this study are
presented in detail in Table 1. Patients clinically classiﬁed
as having persistent AF were more likely to have a cardiac
resynchronization therapy (CRT) device, cardiomyopathy,
and lower LVEF. Patients with persistent AF also had
higher AF burdens; however, a signiﬁcant overlap in AF
burdens was observed between the 2 clinical classiﬁcation
groups (Figs. 1 and 2). When the patients were classiﬁed by
device-derived deﬁnitions, the increase in AF classiﬁcation
(no AF / paroxysmal / persistent / permanent) was
accompanied by a more demarcated increase in AF burden
with far less overlap between the categories (Table 1, Fig. 3).
AF characteristics between the clinical classiﬁcation
groups. A total of 377 patients who had been classiﬁed
clinically as paroxysmal (34.5%) and 22 patients classiﬁed
clinically as persistent (21.2%) did not experience any AF
within their respective observation period (mean 349  40
days, median 365 days, range 181 to 365 days) (Table 2).
Twenty-two patients (2.0%) who had been classiﬁed clini-
cally as paroxysmal and 14 patients (13.4%) classiﬁed clini-
cally as persistent experienced continuous atrial ﬁbrillation
(AF burden >0.95%; all monitored days with >23 h AF)
throughout their respective observation time (mean 347 
45 days, median 365 days, range 195 to 365 days) (Table 2).
Figure 1 shows the distribution of the AF burdens
observed in the paroxysmal and persistent clinical AF clas-
siﬁcation groups. The paroxysmal group had lower AF
burden (mean 0.095  0.221, median 0.001, range 0 to 1)
than the persistent group (mean 0.304  0.385, median
0.04, range 0 to 1, p < 0.0001), and there was a signiﬁcant
overlap in the distribution of the AF burden between the 2
clinical classiﬁcation groups (Figs. 1 and 2).AF characteristics within the clinical classiﬁcation
groups. The results shown in Figures 1 and 2 depict not
only that clinical AF classiﬁcation poorly reﬂects the tem-
poral persistence of AF but also that patients in the same AF
class may vary considerably in terms of their actual temporal
AF persistence (Figs. 1 and 2, Table 2). Although patients
clinically classiﬁed as persistent had higher AF burden this
did not result in signiﬁcant discrimination ability (Fig. 4).
Even at very high AF burden levels, the majority of patients
were classiﬁed as having paroxysmal AF (Figs. 1 and 2, right
panel). Figure 2 (right) shows that the probability of being
classiﬁed in the persistent group did not increase substan-
tially with increasing AF burden. Similarly, receiver-operator
characteristic analyses (Fig. 4) revealed that the discrimina-
tion ability of AF burden, although statistically signiﬁcant,
was poor (area under the curve: 0.671; 95% conﬁdence in-
terval: 0.612 to 0.73; p < 0.001). Within the same clinical
AF class, there was a high heterogeneity in terms of tem-
poral AF persistence (Figs. 1 and 2, Table 2).
Factors inﬂuencing clinical AF classiﬁcation. Although
AF burden did inﬂuence the clinical classiﬁcation of a patient
as persistent AF (6.1/per unit AF burden increase; 95% CI:
3.0 to 12.3/per unit AF burden; p < 0.0001), additional
factors independently inﬂuenced the classiﬁcation of patients.
Factors that were independently associated with a lower
probability of being classiﬁed as persistent AF for the same
level of AF burden included a higher LVEF (odds ratio [OR]
0.97/per unit; 95% CI: 0.95 to 0.98/per unit; p< 0.0001) and
the presence of coronary artery disease (OR: 0.53; 95%CI: 0.32
to 0.88; p ¼ 0.01) (Fig. 5). However, it should be noted that
even at very high AF burden levels (Figs. 1, 2 [right], and 5),
only a minority of patients were clinically classiﬁed as having
persistent AF.
The effect of LVEF and the presence of coronary artery
disease on the clinical AF classiﬁcation did not depend on
the different study (TRENDS or OMNI trials) populations
(OR: 1.014; 95% CI: 0.981 to 1.049, p ¼ 0.40 for the
interaction between LVEF and study; OR: 0.36; 95% CI:
0.10 to 1.21, p ¼ 0.11 for the interaction between presence
of coronary artery disease and study).
Classiﬁcation of AF on the basis of device-derived
criteria. AF classiﬁcation derived from continuous moni-
toring data reﬂected the temporal persistence of AF with
greater accuracy and with less overlap between the AF classes.
The AF burden distribution of the device-derived classiﬁ-
cation groups is more homogenous within each group and
more demarcated between groups (Fig. 3, left). Additionally,
the device-derived classiﬁcations more closely reﬂect the in-
creases in AF burden (Fig. 3, right). As the AF burden in-
creases, the probability of being classiﬁed in a more severe
category also increases, with less overlap between categories
(Fig. 3, right). Patient characteristics and demographics did
not inﬂuence the device-based AF classiﬁcation.
The cross tabulation of this patient population between the
clinical and device AF classiﬁcation schemes is displayed in
Table 2. There was little agreement between the clinical AF
Table 1 Demographics, Classiﬁcation, and Key Characteristics of the Patient Population and Subgroups
Clinical AF Classiﬁcation Device AF Classiﬁcation
Total Result
(n ¼ 1,195)
Paroxysmal
(n ¼ 1,091)
Persistent
(n ¼ 104) p Value
No AF
(n ¼ 399)
Paroxysmal
(n ¼ 543)
Persistent
(n ¼ 217)
Permanent
(n ¼ 36) p Value
TRENDS study 552 (50.6%) 35 (33.7%) 209 (52.4%) 271 (49.9%) 97 (44.7%) 10 (27.8%) 587
OMNI study 539 (49.4%) 69 (66.3%) 190 (47.6%) 272 (50.1%) 120 (55.3%) 26 (72.2%) 608
Device type
CRT 205 (18.8%) 36 (34.6%) <0.001 89 (22.3%) 80 (14.7%) 59 (27.2%) 13 (36.1%) <0.001 241
ICD 316 (29%) 26 (25%) 0.45 131 (32.8%) 155 (28.5%) 46 (21.2%) 10 (27.8%) 0.02 342
IPG 570 (52.2%) 42 (40.4%) 0.02 179 (44.9%) 308 (56.7%) 112 (51.6%) 13 (36.1%) <0.001 612
Clinical classiﬁcation
Paroxysmal 1,091 0 377 (94.5%) 509 (93.7%) 183 (84.3%) 22 (61.1%) 1,091
Persistent 0 104 22 (5.5%) 34 (6.3%) 34 (15.7%) 14 (38.9%) 104
Age, yrs 73.1  10.0 (35.7–100) 71.9  11.1 (21.6–92.4) 0.36 72.6  10.2 (36.7–94.9) 72.7  10.3 (35.7–97.6) 74.1  9.8 (21.6–100) 74.8  9.5 (50.1–87.5) 0.18 73.0  10.1 (21.6–100)
Female 403 (36.9%) 35 (33.7%) 0.58 148 (37.1%) 214 (39.4%) 70 (32.3%) 6 (16.7%) 0.02 438
Follow-up time, days 349.3  39.3 (181–365) 346.0  45.1 (186–365) 0.31 348.7  39.5 (181–365) 350.2  38.6 (182–365) 346.9  42.8 (182–365) 346.7  45.1 (195–365) 0.17 349.0  39.8 (181–365)
LVEF, % 43.0  18.2 (10–91) 33.9  17.6 (10–73) <0.001 41.7  18.1 (10–80) 43.4  18.4 (10–91) 41.1  19.1 (10–80) 35.5  15.4 (15–60) 0.11 42.1  18.4 (10–91)
AF burden 0.1  0.22 (0–1) 0.3  0.38 (0–1) <0.001 0  0 (0–0) 0.03  0.07 (0–0.62) 0.39  0.27 (0.02–0.95) 0.99  0.01 (0.95–1) <0.001 0.11  0.25 (0–1)
Atrial pacing (% of time) 55.8  35.2
61.8; 23.1–90.4
51.6  36.5
51.0; 14.9–88.1
0.25 58.0  37.3
66.5; 18.3–95.2
61.6  32.7
71.9; 32.9–92.1
44.3  30.0
40.6; 16.6–72.1
0.9  1.2
0.5; 0–1.3
<0.001 55.4  35.3
60.9; 22.5–90.1
Coronary artery disease 653 (59.9%) 53 (51%) 0.1 272 (68.2%) 282 (51.9%) 131 (60.4%) 21 (58.3%) <0.001 706
Hypertension 817 (74.9%) 78 (75%) 0.99 295 (73.9%) 412 (75.9%) 166 (76.5%) 22 (61.1%) 0.22 895
Diabetes 294 (26.9%) 25 (24%) 0.6 115 (28.8%) 138 (25.4%) 55 (25.3%) 11 (30.6%) 0.6 319
Cardiomyopathy 537 (49.2%) 66 (63.5%) 0.01 216 (54.1%) 248 (45.7%) 118 (54.4%) 21 (58.3%) 0.02 603
History of atrial ﬂutter 178 (16.3%) 17 (16.3%) 0.99 40 (10%) 110 (20.3%) 39 (18%) 6 (16.7%) <0.001 195
History of atrial tachycardia 60 (5.5%) 6 (5.8%) 0.99 17 (4.3%) 37 (6.8%) 10 (4.6%) 2 (5.6%) 0.34 66
History of AF ablation 77 (7.1%) 14 (13.5%) 0.03 16 (4%) 50 (9.2%) 18 (8.3%) 7 (19.4%) <0.001 91
History of AV node ablation 29 (2.7%) 4 (3.8%) 0.7 9 (2.3%) 17 (3.1%) 5 (2.3%) 2 (5.6%) 0.59 33
Functional status (NYHA
functional class)
None 406 (37.2%) 25 (24%) 0.01 131 (32.8%) 227 (41.8%) 67 (30.9%) 6 (16.7%) <0.001 431
I 90 (8.2%) 5 (4.8%) 0.3 29 (7.3%) 46 (8.5%) 16 (7.4%) 4 (11.1%) 0.79 95
II 234 (21.4%) 18 (17.3%) 0.38 95 (23.8%) 108 (19.9%) 42 (19.4%) 7 (19.4%) 0.44 252
III 222 (20.3%) 37 (35.6%) <0.001 92 (23.1%) 97 (17.9%) 58 (26.7%) 12 (33.3%) 0.01 259
IV 15 (1.4%) 4 (3.8%) 0.12 5 (1.3%) 11 (2%) 2 (0.9%) 1 (2.8%) 0.59 19
Cardiac surgery 388 (35.6%) 37 (35.6%) 0.99 164 (41.1%) 174 (32%) 72 (33.2%) 15 (41.7%) 0.02 425
CABG 336 (30.8%) 27 (26%) 0.36 146 (36.6%) 147 (27.1%) 57 (26.3%) 13 (36.1%) <0.001 363
AVR 52 (4.8%) 5 (4.8%) 0.99 19 (4.8%) 24 (4.4%) 12 (5.5%) 2 (5.6%) 0.92 57
MVR 62 (5.7%) 7 (6.7%) 0.82 24 (6%) 30 (5.5%) 14 (6.5%) 1 (2.8%) 0.82 69
TVR 8 (0.7%) 0 (0%) 0.8 2 (0.5%) 4 (0.7%) 2 (0.9%) 0 (0%) 0.88 8
Values are n (%), mean  SD, or median; interquartile range (ﬁrst, third quartile).
AF ¼ atrial ﬁbrillation; AV ¼ aortic valve; AVR ¼ aortic valve replacement/repair; CABG ¼ coronary artery bypass graft surgery; CRT ¼ cardiac resynchronization therapy; ICD ¼ implantable cardioverter-deﬁbrillator; IPG ¼ implantable pulse generator; LVEF ¼ left ventricular
ejection fraction; MVR ¼ mitral valve replacement/repair; NYHA ¼ New York Heart Association; TVR ¼ tricuspid valve replacement/repair.
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Figure 1
Distribution of AF Burden in Patients With Documented
AF According to the Clinical AF Classiﬁcation
Distribution of atrial ﬁbrillation (AF) burden in patients with documented AF ac-
cording to the clinical AF classiﬁcation. The 399 patients with no documented AF
(377 classiﬁed as paroxysmal and 22 classiﬁed as persistent) were excluded from
this graph.
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2844classiﬁcation and the objective and quantitative measures of
AF temporal persistence (Cohen’s kappa: 0.12, 95% CI: 0.05
to 0.18). Overall, only 46.7% of the clinically classiﬁed
paroxysmal AF patients were also classiﬁed as paroxysmal AF
using the more objective device-related criteria. For the
persistent AF classiﬁcation this agreement dropped to 32.7%.
Discussion
The present study has 3 primary ﬁndings. First, the currently
used clinical AF classiﬁcations poorly reﬂect the temporal
persistence of AF. Second, patients classiﬁed in the same
clinical AF class may be inherently heterogeneous in terms
of temporal AF persistence. Third, certain clinical patient
characteristics appear to inﬂuence the decision to clinically
classify AF. These ﬁndings have important implications
for communication, therapy selection, and clinical trials
involving AF patients.
Implications for communication. Current AF classiﬁca-
tions attempt to communicate information about the persis-
tence andmagnitude of an individual patient’s AF recurrence.
Our results indicate a frequent discordance between the
clinical assessment of AF and the actual amount of AF, which
in our patient population could be precisely measured by
continuous arrhythmia monitoring.
Clinical AF classiﬁcations appear to have an element of
subjectivity to them. For example, although the deﬁnition
for persistent AF includes a minimal duration requirementof >7 days, it also allows for the possibility of pharmacologic
or electrical cardioversion to be a component of the criteria
(1,2). The threshold for seeking cardioversion may differ
among patients with identical arrhythmia burden and the
threshold for administering cardioversion may also differ
among physicians.
The clinical AF classiﬁcation is often employed not only
to evaluate the magnitude and persistence of the arrhythmia
but also to denote the stage or degree of disease progression,
implying that patients with “paroxysmal” AF are at earlier
stages of the disease than patients with “persistent” AF. It is
well recognized that “atrial ﬁbrillation begets atrial ﬁbrilla-
tion” (23) and that in the long term there is a signiﬁcant
progression of AF (15,16), which manifests as a progressive
increase in the temporal persistence of AF. However, the
discordance that we observed between clinical AF classiﬁ-
cations and objective temporal AF indices suggests that the
clinical classiﬁcation of AF is an unreliable indicator for
disease progression. Our ﬁndings suggest that patients with
vastly different degrees of temporal AF persistence (and
stages of disease) within the same clinical classiﬁcation
(Fig. 2, left) may exist. Furthermore, there may also be
patients that, although classiﬁed as having “paroxysmal” AF,
have higher degrees of temporal AF persistence (and thus
are at a later stage of the disease) than patients classiﬁed as
having “persistent” AF (Fig. 2, right). If the staging of the
AF disease can be reﬂected from its temporal persistence,
then the current clinical AF classiﬁcations are unreliable
indicators of the disease progression.
In contrast, although device-based deﬁnitions may seem
somewhat arbitrary, they were designed to align with pub-
lished guidelines (1) and have been used in several AF trials
(11,13–17). Such deﬁnitions have the advantage of being
consistent and reproducible, and are based on objective
temporal AF indices. The AF burden distribution of the
device-derived classiﬁcation groups was more homogenous
within each group and more demarcated between groups
(Fig. 3, left) and the device-derived classiﬁcations more
closely reﬂect the increases in AF burden (Fig. 3, right).
Also as the AF burden increased, the probability of being
classiﬁed in a more severe device-derived category also
increased, with less overlap between categories (Fig. 3,
right). Patient characteristics and demographics did not
inﬂuence the device-based AF classiﬁcation.
Implications for therapy selection. AF classiﬁcation can
strongly affect therapy selection, most importantly the de-
cision to pursue a rhythm control or rate control strategy.
Even once a particular treatment strategy has been decided,
the procedural attributes of a speciﬁc therapy (e.g., AF
ablation as a rhythm control strategy) can be inﬂuenced by
the perceived persistence of the arrhythmia.
Rhythm control is generally attempted as ﬁrst line therapy
in patients with paroxysmal AF. As the disease progresses to
persistent and permanent AF, a rate control approach is
often adopted. A recent survey from the European Heart
Rhythm Association showed that a patient’s clinical AF
Figure 2 Clinical AF Classiﬁcation
(Left) Distribution of the atrial ﬁbrillation (AF) burden in the clinical classiﬁcation groups (paroxysmal, persistent) (p < 0.001). (Right) The probability of being in either of the
clinical classiﬁcation groups at any given AF burden level (conditional density plot). For example, at an AF burden of 0.2, the probability of being classiﬁed as “paroxysmal” or
“persistent” was approximately 0.8 and 0.2, respectively. As the AF burden increases, intuitively one would expect that the probability of being classiﬁed as “paroxysmal” AF
decreases and the probability of being classiﬁed as “persistent” increases. Unexpectedly, at AF burdens of 0.9, the probability of being classiﬁed as “paroxysmal” or
“persistent” was also approximately 0.8 and 0.2, respectively, showing the disconnection between clinical classiﬁcation and temporal persistence. Even at very high burdens
the vast majority of patients were classiﬁed as having “paroxysmal” AF.
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2845classiﬁcation can affect the choice of therapeutic treatment
(7). For example, only 3.1% of patients deemed to be in
persistent AF were selected to undergo “upstream” therapy,
whereas 3 times as many patients (9.4%) classiﬁed as having
paroxysmal AF were selected for this therapy. Furthermore,Figure 3 Device-Derived AF Classiﬁcation
(Left) Distribution of the atrial ﬁbrillation (AF) burden in the device classiﬁcation groups (no
device classiﬁcation groups at any given AF burden level (conditional density plot). As AF
classiﬁcation (no AF/ paroxysmal/ persistent/ permanent) increases. This is in cothe choice of therapy had a strong inﬂuence on the subse-
quent rigor of arrhythmia monitoring.
Imprecise AF classiﬁcation may also affect the perceived
and reported efﬁcacy of speciﬁc rhythm control procedures.
In the case of AF ablation for rhythm control, it is generallyAF, paroxysmal, persistent, permanent). (Right) The probability of being in any of the
burden increases, the probability of being classiﬁed in a progressively more severe
ntrast to the clinical AF classiﬁcation (Fig. 2, right panel).
Table 2 Cross Tabulation of the Clinical and Device-Derived AF Classiﬁcations
Clinical AF
Classiﬁcation
Device Classiﬁcation
No AF
AF Burden <0.001
(n ¼ 399)
Paroxysmal
At Least 1 Day With >5 Min AF But
<7 Consecutive Days With >23 H of AF
(n ¼ 543)
Persistent
At Least 7 Consecutive Days
With >23 H AF
(n ¼ 217)
Permanent
All Monitored Days
With >23 H AF
(n ¼ 36)
Paroxysmal
(n ¼ 1,091)
377 509 183 22
Persistent
(n ¼ 104)
22 34 34 14
AF ¼ atrial ﬁbrillation.
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2846accepted that pulmonary vein isolation alone is sufﬁcient for
paroxysmal AF patients whereas additional lesions are also
required to maintain sinus rhythm in patients with more
advanced, persistent AF. A potential explanation for lack of
complete efﬁcacy with the pulmonary vein isolation only
approach is that some of the patients perceived to have
paroxysmal AF may actually have a more persistent form of
the disease. Likewise, performing additional lesions in
patients thought to have persistent AF could expose them to
unnecessary increased risk if in fact they have a more
paroxysmal form of the disease. More accurate classiﬁcation
may allow us to better align appropriate therapies to
appropriate patients and balance the respective risks and
beneﬁts of these therapies.Figure 4
Receiver-Operating Characteristic Curve
for the Discrimination Ability of AF Burden on
Clinical AF Classiﬁcation
Receiver-operating characteristic curve for the discrimination ability of atrial
ﬁbrillation (AF) burden on clinical AF classiﬁcation. AF burden has a statistically
signiﬁcant, albeit poor, discrimination ability (area under the curve [AUC]: 0.67;
95% conﬁdence interval: 0.61 to 0.73; p < 0.001).Implications for clinical trials. Accurate categorization of
patients into the various clinical AF classiﬁcations affects
both our ability to study a homogenous cohort, as well as our
ability to precisely assess the treatment effects when AF
recurrence or progression is an endpoint. Clinical trials
frequently attempt to enroll patients with only paroxysmal
AF (8,24), only persistent AF (25), or both types of AF (26)
with the goal of evaluating the effect of a therapy within a
speciﬁc patient population or comparing the effect between
patient populations. Therefore it is important that these
study cohorts are as uniform as possible with respect to the
magnitude of AF as a disease. Our results suggest that there
may be signiﬁcant “blurring” of these AF classiﬁcations in
clinical practice, thereby making the interpretation of suchFigure 5
The Logistic Regression Model Evaluating the Effect
of LVEF and CAD on the Clinical AF Classiﬁcation
The logistic regression model evaluating the effect of left ventricular ejection
fraction (LVEF) and coronary artery disease (CAD) on the clinical AF classiﬁcation.
Both LVEF and the CAD signiﬁcantly and independently inﬂuenced the clinical atrial
ﬁbrillation (AF) classiﬁcation. At the same level of AF burden, patients with different
LVEF and presence or absence of CAD were classiﬁed differently. It should also be
noted that even at very high AF burdens, only a minority of patients was classiﬁed
as having persistent AF.
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2847studies a challenge. For example, we observed that 54% of
patients classiﬁed as having persistent AF at baseline did not
meet the threshold of having at least 7 consecutive days of
AF despite an mean follow-up of almost 1 year.
Similarly, trials using AF recurrence (27) or the progression
to persistent AF (28) as study endpoints are prone to error in
the absence of comprehensive rhythm monitoring. AF
recurrence and progression are typically assessed via inter-
mittent periods of external monitoring and/or patient-
reported symptoms. It is well established that these brief
monitoring snapshots do not accurately capture the true
arrhythmia status (5,6,29) and that relying on patient symp-
toms can lead to both under-reporting and over-reporting
of AF (3,4,30). Long-term arrhythmia monitoring helps to
mitigate these errors by providing objective measures of the
arrhythmia persistence (31). A more accurate classiﬁcation of
patients on the basis of objective criteria of AF persistence
may lead to better identiﬁcation and selection of patients that
will more likely respond to the appropriate therapy. The advent
of smaller implantable monitoring devices (32,33) and more
comfortable external patches (34) is likely to increase the number
of patients in whom this type of data is available in the future.
Role of patient characteristics. One striking ﬁnding of
this study was that patients’ clinical characteristics appear to
have inﬂuenced the clinical AF classiﬁcation. In particular,
patients with reduced LVEF were more likely to be char-
acterized as having persistent AF for the same level of AF
burden. Additionally, patients with coronary artery disease
were more likely to be classiﬁed as having paroxysmal AF,
for the same level of AF burden and LVEF. An interpre-
tation of this ﬁnding can only be speculative at this point.
Perhaps in sicker patients (with low LVEF), the perception
of AF may be more prominent, or the same amount of AF
may generate a more severe symptomatology, causing phy-
sicians to subsequently classify the patient’s AF as more
severe. In contrast, patients with coronary artery disease were
less likely to be classiﬁed as having persistent AF for the
same level of AF burden and LVEF. A potential explanation
for this ﬁnding could be that in some patients with coronary
artery disease, the occurrence of AF may be more likely
attributed to the underlying coronary artery disease and not
to the “AF process” itself. Regardless of the explanation for
the above ﬁndings, it remains true that clinical patient fac-
tors other than the temporal persistence of AF inﬂuenced
the clinical classiﬁcation of AF.
The inﬂuence of symptomatology on AF classiﬁcation.
Although the guidelines do not explicitly take the degree of
AF-related symptomatology into consideration, patient
symptoms may inﬂuence the clinical AF classiﬁcation. Pa-
tients with higher symptomatology regardless of the temporal
AF persistence may seek medical attention more frequently,
thus allowing for more frequent documentation of their
rhythm status. Patients with other co-morbidities such as low
ejection fraction may exhibit more severe symptomatology
for the same level of temporal AF persistence. Furthermore,
the degree of AF-related symptoms may inﬂuence thephysician’s decision to attempt cardioversion which, when
performed, simultaneously reclassiﬁes a patient to the
“persistent” AF class regardless of the degree and magnitude
of the temporal AF persistence. If the degree of AF disease is
reﬂected by the temporal AF persistence, the patient’s
symptomatology has been shown to poorly correlate with the
AF temporal persistence (4) and may signiﬁcantly inﬂuence
and blur the clinical AF classiﬁcation.
Study limitations. AF is not a static disease and therefore it
is possible that although the physician assessment of rhythm
status was accurate at the time it was made, AF may have
progressed over time. However, the relatively brief follow-up
period of <1 year should have minimized the extent of AF
progression. Furthermore, AF progression cannot account
for patients who “improved” their AF classiﬁcation (e.g., a
patient deemed to have persistent AF who was found to not
have any AF).
We did not have thorough reporting of all interventions
and changes in medical regimens, and therefore AF may
have improved in some patients due to implementation of
effective therapies. However, we attempted to minimize this
issue by including patients from observational (noninter-
ventional) studies and excluding patients with obvious AF
treatments.
All patients had clinical indications for a pacemaker or
implantable cardioverter-deﬁbrillator. Therefore these re-
sults theoretically may not apply to the broader population of
patients without an implantable device indication. However,
small subcutaneous devices are now available which provide
similar AF monitoring capabilities to patients without
traditional implantable device indications (33).
In the present study, the AF classiﬁcation was performed
before the observation period and therefore the physicians
were not able to re-evaluate the AF classiﬁcation on the basis
of new information. AF classiﬁcations were not assessed at
the end of the study. Although this is a limitation, the
design of the present study design is appropriate to inves-
tigate the disconnect between AF classiﬁcation and AF
temporal persistence when the AF classiﬁcation is used as an
inclusion criterion as in clinical trials (such as the present
study where AF classiﬁcation was performed before the
observation period), as well as the disconnect between the
clinical classiﬁcation as a “belief” on the staging of the AF
disease, and the objective temporal AF persistence.
Conclusions
Clinical AF classiﬁcations poorly reﬂect its temporal
persistence and clinical patient characteristics signiﬁcantly
inﬂuence the clinical categorization of AF. Our results
demonstrate that patients classiﬁed in identical traditional
clinical AF categories may be inherently heterogeneous with
regards to AF temporal persistence. Further study is required
to determine if classifying AF on the basis of rigorous
arrhythmia monitoring can improve clinical outcomes rela-
tive to traditional clinical assessments.
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